Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki¹, Rika Sakai², Noriko Iwaki³, Go Yamamoto⁴, Kayoko Murayama⁵, Momoko Nishikori⁶, Kazutaka Sunami⁷, Isao Yoshida⁸, Hiroki Yano⁹, Naoki Takahashi¹⁰, Akinao Okamoto¹¹, Saori Munemoto¹², Aiko Sawazaki¹³, Youko Suehiro¹⁴, Noriko Fukuhara¹⁵, Atsushi Wake¹⁶, Ayako Arai¹⁷, Yasufumi Masaki¹⁸, Kohtaro Toyama¹⁹, Akihiro Yokoyama²⁰, Hiroko Tsunemine²¹, Yuichi Hasegawa²², Kenji Matsumoto²³, Tomomi Yamada²⁴, Yuki Nishimura¹, Satoshi Tamaru¹, Naoko Asano²⁵, Kohta Miyawaki²⁶, Koji Izutsu²⁷, Tomohiro Kinoshita²⁸, Ritsuro Suzuki²⁹, Koichi Ohshima³⁰, Koji Kato²⁶, Naoyuki Katayama¹, Motoko Yamaguchi¹

Affiliations

¹ Mie University, Tsu, Japan.
² Kanagawa Cancer Center, Yokohama, Japan.
³ Kanazawa University, Kanazawa, Japan.
⁴ Toranomon Hospital, Tokyo, Japan.
⁵ Gunma Cancer Center, Ohta, Japan.
⁶ Kyoto University, Kyoto, Japan.
⁷ Okayama Medical Center, Okayama, Japan.
⁸ Shikoku Cancer Center, Matsuyama, Japan.
⁹ Kainan Hospital, Yatomi, Japan.
¹⁰ Saitama Medical University, Hidaka, Japan.
¹¹ Fujita Medical University, Toyoake, Japan.
¹² Keiju Medical Center, Kanazawa, Japan.
¹³ Fukui-ken Saiseikai Hospital, Fukui, Japan.
¹⁴ Kyushu Cancer Center, Fukuoka, Japan.
¹⁵ Tohoku University, Sendai, Japan.
¹⁶ Toranomon Hospital Kajigaya, Kajigaya, Japan.
¹⁷ St. Marianna University, Kawasaki, Japan.
¹⁸ Kanazawa Medical University, Ishikawa, Japan.
¹⁹ Fujioka General Hospital, Fujioka, Japan.
²⁰ Tokyo Medical Center, Tokyo, Japan.
²¹ Shinko Hospital, Kobe, Japan.
²² University of Tsukuba, Tsukuba, Japan.
²³ Yokohama City University, Yokohama, Japan.
²⁴ Osaka University, Suita, Japan.
²⁵ Shinshu Medical Center, Suzaka, Japan.
²⁶ Kyushu University, Fukuoka, Japan.
²⁷ National Cancer Center Hospital, Tokyo, Japan.
²⁸ Aichi Cancer Center Hospital, Nagoya, Japan.
²⁹ Shimane University, Izumo, Japan.
³⁰ Kurume University, Kurume, Japan.

PMID: 36929591
PMCID: PMC10236623
DOI: 10.1111/cas.15784

Clinical Trial

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki et al. Cancer Sci. 2023 Jun.

. 2023 Jun;114(6):2689-2691.

doi: 10.1111/cas.15784. Epub 2023 Mar 16.

Authors

Affiliations

¹ Mie University, Tsu, Japan.
² Kanagawa Cancer Center, Yokohama, Japan.
³ Kanazawa University, Kanazawa, Japan.
⁴ Toranomon Hospital, Tokyo, Japan.
⁵ Gunma Cancer Center, Ohta, Japan.
⁶ Kyoto University, Kyoto, Japan.
⁷ Okayama Medical Center, Okayama, Japan.
⁸ Shikoku Cancer Center, Matsuyama, Japan.
⁹ Kainan Hospital, Yatomi, Japan.
¹⁰ Saitama Medical University, Hidaka, Japan.
¹¹ Fujita Medical University, Toyoake, Japan.
¹² Keiju Medical Center, Kanazawa, Japan.
¹³ Fukui-ken Saiseikai Hospital, Fukui, Japan.
¹⁴ Kyushu Cancer Center, Fukuoka, Japan.
¹⁵ Tohoku University, Sendai, Japan.
¹⁶ Toranomon Hospital Kajigaya, Kajigaya, Japan.
¹⁷ St. Marianna University, Kawasaki, Japan.
¹⁸ Kanazawa Medical University, Ishikawa, Japan.
¹⁹ Fujioka General Hospital, Fujioka, Japan.
²⁰ Tokyo Medical Center, Tokyo, Japan.
²¹ Shinko Hospital, Kobe, Japan.
²² University of Tsukuba, Tsukuba, Japan.
²³ Yokohama City University, Yokohama, Japan.
²⁴ Osaka University, Suita, Japan.
²⁵ Shinshu Medical Center, Suzaka, Japan.
²⁶ Kyushu University, Fukuoka, Japan.
²⁷ National Cancer Center Hospital, Tokyo, Japan.
²⁸ Aichi Cancer Center Hospital, Nagoya, Japan.
²⁹ Shimane University, Izumo, Japan.
³⁰ Kurume University, Kurume, Japan.

PMID: 36929591
PMCID: PMC10236623
DOI: 10.1111/cas.15784

No abstract available

PubMed Disclaimer

Conflict of interest statement

KMiyazaki reports research funding (Kyowa Kirin, Zenyaku). RSakai reports honoraria (Chugai, Takeda, Kyowa Kirin, Bristol Myers Squibb); research funding (Chugai, Kyowa Kirin). KS reports honoraria (Bristol Myers Squibb); research funding (Takeda, Bristol Myers Squibb, Chugai, Kyowa Kirin). IY reports honoraria (Chugai, Kyowa Kirin, Takeda); research funding (Chugai, Kyowa Kirin); NT reports honoraria (Takeda); research funding (Bristol Myers Squibb, Kyowa Kirin). YS reports honoraria (Chugai, Takeda, Kyowa Kirin, Bristol Myers Squibb, Pfizer); research funding (Chugai, Kyowa Kirin). NF reports honoraria (Bristol Myers Squibb, Chugai, Kyowa Kirin, Takeda, Zenyaku); research funding (Chugai). AA reports research funding (Chugai). YM reports research funding (Kyowa Kirin, Asahi Kasei, Takeda, Chugai). AY reports honoraria (Kyowa Kirin, Chugai, Takeda, Bristol Myers Squibb); research funding (Kyowa Kirin). KMiyawaki reports honoraria (Chugai). KI reports research funding (Bristol Myers Squibb, Pfizer, Kyowa Kirin, Chugai). RSuzuki reports honoraria (Chugai, Kyowa Kirin, Bristol Myers Squibb, Takeda); research funding (Chugai, Kyowa Kirin, Shionogi). KK reports honoraria (Kyowa Kirin, Chugai); research funding (Chugai, Takeda, Kyowa Kirin, Bristol Myers Squibb). NK reports research funding (Kyowa Kirin). MY reports research funding (Kyowa Kirin, Chugai). The other authors have nothing to disclose. Tomohiro Kinoshita, Koichi Ohshima, and Ritsuro Suzuki are editorial board members of Cancer Science.

Figures

**FIGURE 1**
Survival curves for patients with CD5‐positive (CD5⁺) DLBCL with a median follow‐up of 6.0 years. (A) PFS and (B) OS for all patients (n = 47).

**FIGURE 2**
Survival according to COO categories. (A) PFS and (B) OS according to COO categories (n = 46).

**FIGURE 3**
Probability of CNS relapse in CD5⁺ DLBCL patients (n = 47).

See this image and copyright information in PMC

References

1. Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5‐positive diffuse large B‐cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22:1601‐1607. - PubMed
1. Miyazaki K, Asano N, Yamada T, et al. DA‐EPOCH‐R combined with high‐dose methotrexate in patients with newly diagnosed stage II‐IV CD5‐positive diffuse large B‐cell lymphoma: a single‐arm, open‐label, phase II study. Haematologica. 2020;105:2308‐2315. - PMC - PubMed
1. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B‐cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93:1195‐1202. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Affiliations

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources